All news

Syndax rated Moderate Buy with $41.80 target

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Syndax Pharmaceuticals (NASDAQ:SNDX) carries a "Moderate Buy" consensus rating from eleven sell-side analysts, with an average 12-month price target of $41.80 versus a current price of

Read original source

SNDX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.